SEHK:1548Life Sciences
Genscript Biotech (SEHK:1548) Is Down 7.6% After Strong CARVYKTI Sales Update Has The Bull Case Changed?
In the past quarter, Genscript Biotech’s associate Legend Biotech reported approximately US$555 million in net trade sales of its multiple myeloma cell therapy CARVYKTI® for Q4 2025, while also highlighting the usual development, regulatory, and competitive risks facing such products.
This sales performance underlines how CARVYKTI® has become an important proof point for Genscript’s broader biotech platform and positioning in advanced therapies.
We’ll examine how CARVYKTI®’s commercial...